Atul Chopra, MD, PhD
-
Specialty: Genetics
View Expertise -
Primary Location: 11100 Euclid Ave (0 mi.)
Other Locations - Languages Spoken: English
Office Locations
DO Lakeside 1500 (0 mi.)
11100 Euclid Ave
Lakeside Ste 1500
Cleveland, OH 44106
216-844-3936
Biography: Atul Chopra, MD, PhD
Expertise
Titles
- Associate Director, Rare Disease Program, Harrington Discovery Institute, University Hospitals
- Investigator, Harrington Discovery Institute, University Hospitals
- Associate Professor of Medicine, CWRU School of Medicine
- Assistant Professor of Genetics, CWRU School of Medicine
Certifications & Memberships
- Clinical Genetics and Genomics - American Board of Medical Genetics and Genomics
Education
Residency | Medical Genetics
Medical Genetics - Texas Children's Hospital (2010 - 2014)
Other Education
Baylor College Of Medicine (2010)
Medical Education
Maharashtra Institute Of Medical Education And Research (2002)
About
Atul Chopra, MD, PhD, is a physician-scientist and medical geneticist specializing in rare genetic disorders of metabolism and energy balance. An example of his work is the discovery of asprosin, a hormone that controls appetite and glucose levels, that was made possible by clinical examination of patients with mutations in a gene never previously associated with such processes.
Dr. Chopra’s lab at Harrington Discovery Institute at University Hospitals, and Case Western Reserve University, Cleveland, studies every facet of asprosin biology - synthesis, secretion, blood dynamics, CNS and hepatic receptors, and manipulation to treat disease. He devotes most of his time to novel scientific discovery as a principal investigator of his lab group, and to diagnosing and caring for patients as an Attending Medical Geneticist at the Center for Human Genetics, University Hospitals Cleveland Medical Center.
Dr. Chopra founded and operationalized Aceragen, Inc., a biotech company that is developing treatments for several rare genetic diseases. His professional life encompasses the entire arc - from caring for patients, to discovering new biology, to commercially developing products that serve those patients. Dr. Chopra also serves as a thought leader in metabolic and hormonal diseases such as obesity, diabetes, metabolic syndrome and certain inborn errors of metabolism.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Atul Chopra did not disclose any Outside Relationships with Industry.